![](https://endpts.com/wp-content/uploads/2021/05/endpts_weekly_FI@x2.jpg)
Merck’s $3B return to eye disease; J&J’s $1.25B tuck-in; Keytruda challenger steals #ASCO24 show; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.